NIRVANA-1: Maintenance therapy with niraparib versus niraparib –bevacizumab in patients with advanced ovarian cancer - supplementary material
收藏数据链接：
官方服务：
资源简介：
<b>Criteria for discontinuing allocated interventions for participant and dose modifications</b>
提供机构：
Taylor & Francis创建时间：
2023-08-31
